The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response

Overview

Journal PLoS Negl Trop Dis

Specialties Infectious Diseases
Tropical Medicine

Date 2015 Jun 13

PMID 26065421

Citations 50

Authors

Jacky Flipse

Jolanda M Smit

Affiliations

Soon will be listed here.

Abstract

Dengue is the most prevalent mosquito-borne viral disease worldwide. Yet, there are no vaccines or specific antivirals available to prevent or treat the disease. Several dengue vaccines are currently in clinical or preclinical stages. The most advanced vaccine is the chimeric tetravalent CYD-TDV vaccine of Sanofi Pasteur. This vaccine has recently cleared Phase III, and efficacy results have been published. Excellent tetravalent seroconversion was seen, yet the protective efficacy against infection was surprisingly low. Here, we will describe the complicating factors involved in the generation of a safe and efficacious dengue vaccine. Furthermore, we will discuss the human antibody responses during infection, including the epitopes targeted in humans. Also, we will discuss the current understanding of the assays used to evaluate antibody response. We hope this review will aid future dengue vaccine development as well as fundamental research related to the phenomenon of antibody-dependent enhancement of dengue virus infection.

Citing Articles

Antiviral activity of myricetin glycosylated compounds isolated from against chikungunya virus.

Munoz A, Cuellar A, Arevalo G, Santamaria B, Rodriguez A, Buendia-Atencio C EXCLI J. 2023; 22:716-731.

PMID: 37662709 PMC: 10471840. DOI: 10.17179/excli2023-6242.

In Silico Comparative Analysis of Predicted B Cell Epitopes against Dengue Virus (Serotypes 1-4) Isolated from the Philippines.

Abesamis L, Aliping E, Armada F, Danao M, Del Valle P, Regencia Z Vaccines (Basel). 2022; 10(8).

PMID: 36016147 PMC: 9415047. DOI: 10.3390/vaccines10081259.

Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.

Thompson D, Guenther B, Manayani D, Mendy J, Smith J, Espinosa D PLoS Negl Trop Dis. 2022; 16(7):e0010588.

PMID: 35793354 PMC: 9292115. DOI: 10.1371/journal.pntd.0010588.

DENV-Mimetic Polymersome Nanoparticles Bearing Multi-Epitope Lipopeptides Antigen as the Next-Generation Dengue Vaccine.

Rahman N, Mohamad Norpi A, Nordin M, Amin M, Fuaad A, Azami N Pharmaceutics. 2022; 14(1).

PMID: 35057051 PMC: 8781246. DOI: 10.3390/pharmaceutics14010156.

A Novel Orf Virus D1701-VrV-Based Dengue Virus (DENV) Vaccine Candidate Expressing HLA-Specific T Cell Epitopes: A Proof-of-Concept Study.

Reguzova A, Fischer N, Muller M, Salomon F, Jaenisch T, Amann R Biomedicines. 2021; 9(12).

PMID: 34944678 PMC: 8698572. DOI: 10.3390/biomedicines9121862.

References

Teoh E, Kukkaro P, Teo E, Lim A, Tan T, Yip A . The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012; 4(139):139ra83. DOI: 10.1126/scitranslmed.3003888. View

Wilder-Smith A . Dengue vaccines: dawning at last?. Lancet. 2014; 384(9951):1327-9. DOI: 10.1016/S0140-6736(14)61142-9. View

Zellweger R, Miller R, Eddy W, White L, Johnston R, Shresta S . Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 2013; 9(10):e1003723. PMC: 3814346. DOI: 10.1371/journal.ppat.1003723. View

Heinz F, Stiasny K . Flaviviruses and flavivirus vaccines. Vaccine. 2012; 30(29):4301-6. DOI: 10.1016/j.vaccine.2011.09.114. View

Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384(9951):1358-65. DOI: 10.1016/S0140-6736(14)61060-6. View

Wan S, Lin C, Wang S, Chen Y, Yeh T, Liu H . Current progress in dengue vaccines. J Biomed Sci. 2013; 20:37. PMC: 3686670. DOI: 10.1186/1423-0127-20-37. View

Sabin A . The dengue group of viruses and its family relationships. Bacteriol Rev. 1950; 14(3):225-32. View

Weiskopf D, Angelo M, Bangs D, Sidney J, Paul S, Peters B . The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. 2014; 89(1):120-8. PMC: 4301095. DOI: 10.1128/JVI.02129-14. View

Sessions O, Tan Y, Goh K, Liu Y, Tan P, Rozen S . Host cell transcriptome profile during wild-type and attenuated dengue virus infection. PLoS Negl Trop Dis. 2013; 7(3):e2107. PMC: 3597485. DOI: 10.1371/journal.pntd.0002107. View

10.

Crill W, Hughes H, Delorey M, Chang G . Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009; 4(4):e4991. PMC: 2659788. DOI: 10.1371/journal.pone.0004991. View

11.

Hss A, Koh M, Tan K, Chan L, Zhou L, Bouckenooghe A . Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine. 2013; 31(49):5814-21. DOI: 10.1016/j.vaccine.2013.10.013. View

12.

Lai C, Williams K, Wu Y, Knight S, Balmaseda A, Harris E . Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis. 2013; 7(9):e2451. PMC: 3777924. DOI: 10.1371/journal.pntd.0002451. View

13.

da Costa V, Marques-Silva A, Floriano V, Moreli M . Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials. Vaccine. 2014; 32(39):4885-92. DOI: 10.1016/j.vaccine.2014.07.008. View

14.

Halstead S, Mahalingam S, Marovich M, Ubol S, Mosser D . Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010; 10(10):712-22. PMC: 3057165. DOI: 10.1016/S1473-3099(10)70166-3. View

15.

Mangada M, Rothman A . Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. 2005; 175(4):2676-83. DOI: 10.4049/jimmunol.175.4.2676. View

16.

Avirutnan P, Zhang L, Punyadee N, Manuyakorn A, Puttikhunt C, Kasinrerk W . Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog. 2007; 3(11):e183. PMC: 2092380. DOI: 10.1371/journal.ppat.0030183. View

17.

Halstead S . Dengue vaccine development: a 75% solution?. Lancet. 2012; 380(9853):1535-6. DOI: 10.1016/S0140-6736(12)61510-4. View

18.

Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U . Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog. 2013; 9(6):e1003458. PMC: 3688551. DOI: 10.1371/journal.ppat.1003458. View

19.

Sirivichayakul C, Sabchareon A, Limkittikul K, Yoksan S . Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand. Virol J. 2014; 11:48. PMC: 3975240. DOI: 10.1186/1743-422X-11-48. View

20.

Murphy B, Whitehead S . Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011; 29:587-619. DOI: 10.1146/annurev-immunol-031210-101315. View